<DOC>
	<DOCNO>NCT01777945</DOCNO>
	<brief_summary>This multicenter observational study evaluate efficacy safety Xeloda ( capecitabine ) combination docetaxel first-line therapy participant HER2-negative metastatic breast cancer . Participants follow approximately 6 month treatment .</brief_summary>
	<brief_title>XEBRA Study : An Observational Study Xeloda ( Capecitabine ) Combination With Docetaxel First Line Participants With HER2-Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age HER2negative metastatic breast cancer Participants initiate firstline therapy Xeloda docetaxel accordance Summary Product Characteristics ; participant start treatment Xeloda docetaxel 3 month enrollment study also eligible Contraindications Xeloda treatment accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>